Christopher James Sampson
Names
| first: |
Christopher |
| middle: |
James |
| last: |
Sampson |
Identifer
Contact
| homepage: |
http://www.chrissampson.me |
|
| phone: |
+44 (0)20 7747 8866 |
| postal address: |
2nd Floor Goldings House,
Hay’s Galleria,
2 Hay’s Lane,
London,
SE1 2HB
UK |
Affiliations
-
Office of Health Economics
Research profile
author of:
- Marginal cost per QALY estimates: What are they good for? (RePEc:eee:hepoli:v:142:y:2024:i:c:s0168851024000460)
by Sampson, Chris & Cookson, Graham - How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy (RePEc:ohe:briefg:002146)
by Chris Sampson;Martina Garau - How is Quality of Life Measured for Health Technology Assessments? (RePEc:ohe:briefg:002357)
by David Mott;Gayathri Kumar;Chris Sampson;Martina Garau - Unknown item RePEc:ohe:conrep:001976 (paper)
- Unknown item RePEc:ohe:conrep:002047 (paper)
- Barriers to Uptake of Minimal Access Surgery in the United Kingdom (RePEc:ohe:conres:001976)
by Paula Lorgelly;Amanda Cole;Phill O’Neill;Chris Sampson - The Impact of New Medicines in the NHS: 70 Years of Innovation (RePEc:ohe:conres:002047)
by Chris Sampson;Phill O’Neill;Paula Lorgelly - The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe (RePEc:ohe:conres:002468)
by Chris Sampson;Edward Oliver;Priscila Radu;Tanja Podkonjak;Lotte Steuten - A Framework for Value-aligned Pricing of Combination Therapies (RePEc:ohe:conres:002490)
by Matthew Napier;Chris Sampson;Amanda Cole;Martina Garau - R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C (RePEc:ohe:grafun:002040)
by Mikel Berdud;Martina Garau;Margherita Neri;Phill O’Neill;Chris Sampson;Adrian Towse - Drop Dead: Is Anchoring at ‘Dead’ a Theoretical Requirement in Health State Valuation? (RePEc:ohe:grafun:002308)
by Chris Sampson;David Parkin;Nancy Devlin - Unknown item RePEc:ohe:respap:002040 (paper)
- Unknown item RePEc:ohe:respap:002308 (paper)
- Cost implications of treatment non-completion in a forensic personality disorder service (RePEc:pra:mprapa:48757)
by Sampson, Christopher & James, Marilyn & Huband, Nick & Geelan, Steve & McMurran, Mary - Happy and healthy: a joint model of health and life satisfaction (RePEc:pra:mprapa:49766)
by Hernández-Alava, Mónica & Sampson, Christopher & Wailoo, Allan - The relationship between individual risk and cost-effectiveness in screening interventions (RePEc:pra:mprapa:51799)
by Sampson, Christopher & James, Marilyn & Whynes, David - Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al (RePEc:sae:medema:v:41:y:2021:i:3:p:255-257)
by Chris Sampson & Isobel Firth & Adrian Towse - Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy (RePEc:spr:aphecp:v:20:y:2022:i:5:d:10.1007_s40258-022-00730-3)
by Chris Sampson & Bernarda Zamora & Sam Watson & John Cairns & Kalipso Chalkidou & Patricia Cubi-Molla & Nancy Devlin & Borja García-Lorenzo & Dyfrig A. Hughes & Ashley A. Leech & Adrian Towse - Do patients registered with CAM-trained GPs really use fewer health care resources and live longer? A response to Kooreman and Baars. Eur J Health Econ (2012). 13:469–776 (RePEc:spr:eujhec:v:14:y:2013:i:4:p:703-705)
by Christopher Sampson & David Whitehurst & Andrew Street - Transparency in Decision Modelling: What, Why, Who and How? (RePEc:spr:pharme:v:37:y:2019:i:11:d:10.1007_s40273-019-00819-z)
by Christopher James Sampson & Renée Arnold & Stirling Bryan & Philip Clarke & Sean Ekins & Anthony Hatswell & Neil Hawkins & Sue Langham & Deborah Marshall & Mohsen Sadatsafavi & Will Sullivan & Edward - Model Registration: A Call to Action (RePEc:spr:pharmo:v:1:y:2017:i:2:d:10.1007_s41669-017-0019-2)
by Christopher James Sampson & Tim Wrightson - NICE and the EQ-5D-5L: Ten Years Trouble (RePEc:spr:pharmo:v:6:y:2022:i:1:d:10.1007_s41669-021-00315-1)
by Chris Sampson - Is anchoring at ‘dead’ a theoretical requirement for health state valuation? (RePEc:wly:hlthec:v:33:y:2024:i:9:p:1929-1935)
by Chris Sampson & David Parkin & Nancy Devlin